Subsequent Events (Details)		1 Months Ended
	Jul. 28, 2020 $ / shares shares	Jul. 31, 2020 USD ($) shares	Jul. 27, 2020 USD ($)	Apr. 23, 2020 USD ($)
Maximum
Subsequent Events
Aggregate public offering price				$ 150,000,000
At The Market Offerings | Maximum
Subsequent Events
Percentage of commission fees to sales agent				3.0
Subsequent Events
Subsequent Events
Vesting period	10 years
Grant date fair value (in dollars per share) | $ / shares	$ 1.46
Subsequent Events | At The Market Offerings
Subsequent Events
Shares issued (in shares) | shares		36,111,471
Net proceeds		$ 58,500,000
Subsequent Events | At The Market Offerings | Maximum
Subsequent Events
Aggregate public offering price			$ 100,000,000
Subsequent Events | CEO
Subsequent Events
Number of shares authorized | shares	2,000,000
Exercise price (in dollars per share) | $ / shares	$ 2.07
Pelican Therapeutics, Inc. | Subsequent Events
Subsequent Events
Aggregate milestone payments		2,000,000
Pelican Therapeutics, Inc. | Subsequent Events | Jeffrey Wolf
Subsequent Events
Aggregate milestone payments		408,318
Pelican Therapeutics, Inc. | Subsequent Events | John Monahan
Subsequent Events
Aggregate milestone payments		5,948
Pelican Therapeutics, Inc. | Subsequent Events | Edward B. Smith
Subsequent Events
Aggregate milestone payments		$ 40,098